Key insights
- AstraZeneca's positive trial results for Tozorakimab, a COPD treatment, boosted its stock. While primarily impacting AstraZeneca, the news signals potential for the IL-33 mechanism in respiratory treatments, contrasting previous failures by Sanofi and Roche. This could positively influence investor sentiment in the broader pharmaceutical sector, particularly companies developing similar monoclonal antibody therapies, but the impact on the overall US equity market is limited.
In this article
AstraZeneca's stock jumped as much as 4% after Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, the company said.
"This marks a notable shift in sentiment, given limited conviction in the IL-33 mechanism following prior IL-33 failures from Sanofi and Roche," said Jefferies analysts.
Tozorakimab and rival drugs belong to a class of treatments called monoclonal antibodies. They work by suppressing the action of the protein interleukin-33 (IL-33) and can reduce inflammation.
London-listed shares were last seen up 3.5% in midday trading, contrasting with the UK's FTSE 100 index which fell 0.6%.
This is a breaking news story. Please refresh for updates.